/** blogpostTitle: GMM Pfaudler Q1 FY27: Strong Orders, A New Global Structure, and the Margin Question blogpostSlug: gmmpfaudler-q1 blogpostCoverImageUrl: null blogpostCoverImageDescription: Ultra-realistic corporate finance scene showing a clean glass-walled boardroom table with a tablet and printed dashboards. The dashboards display a line chart of quarterly revenue trending upward into the latest quarter, a bar chart for order intake hitting a peak near 1000, and a separate line for backlog rising to about 2289. A four-segment donut chart shows division revenue mix (largest slice around half, others around 28%, 14%, 8%). Neutral lighting, professional aesthetic, no logos or text labels. blogpostShortTitle: GMM Pfaudler Q1 FY27 orders and reset */

GMM Pfaudler Q1 FY27: Strong Orders, A New Global Structure, and the Margin Question

GMM Pfaudler reported a solid start to FY27 on the topline, backed by a strong order pipeline and a record backlog. For Q1 FY27, consolidated operational income rose to INR 925 crore, up 16% year on year. EBITDA stood at INR 94 crore, translating into a 10.1% margin. Profit after tax came in at INR 22.1 crore, up 118% year on year, with EPS at INR 5.32.

The quarter’s headline, however, was not only the numbers. Management used the release and the earnings call to explain a structural change in how the group is run and how it will be reported. After several years of acquisition-led expansion, the company is now reorganising into four global technology divisions. The stated intent is to accelerate growth, widen diversification, and improve costs and decision-making across a platform that spans multiple countries and technologies.

Orders stayed strong, and backlog hit a new high

Order intake for the quarter was INR 1,007 crore, up 16% quarter on quarter. Backlog increased to INR 2,289 crore, up 20% year on year and 4% quarter on quarter. Management stressed that the backlog composition has also changed versus last year. In the earnings call, the Group CEO noted that around 30% of Q1 FY26 order intake comprised multi-year projects, while the current order book is largely made up of projects with execution cycles of 10 to 12 months. The implication is higher near-term revenue visibility within FY27.

The company also highlighted that non-traditional industries are gaining share in order intake. In the diversification slide, non-traditional industries increased as a proportion of total order intake across FY24 to FY26, and Q1 FY27 continued that trend. Management pointed to orders won in mining and petrochemical industries during the quarter, and said the pipeline for non-traditional industries remains strong and growing.

Division reporting replaces the old geographic view

From this quarter, GMM Pfaudler presented business performance through four global divisions.

CRT combines glass-lined and fluoropolymer businesses. PPT brings together mixing, filtration and drying, sealing, and membrane separation. HET is an India-based heavy engineering business with exports. PST focuses on process systems, modular solutions, and specialised applications like acid recovery.

Financially, CRT remained the largest division by revenue in Q1 FY27. PPT delivered a strong order intake jump. HET’s order intake was high on a percentage basis due to a low base. PST’s order intake declined sharply year on year due to a high base last year which included a large defence order.

Performance by division: growth drivers were not uniform

By division, Q1 FY27 revenue was INR 466 crore for CRT, INR 255 crore for PPT, INR 74 crore for HET, and INR 131 crore for PST. In order intake, CRT recorded INR 502 crore, PPT INR 367 crore, HET INR 58 crore, and PST INR 80 crore.

On the earnings call, management described pharma as improving, particularly in India, with activity in Hyderabad and CDMO, which supports demand in CRT as well as allied PPT product lines. Chemicals in India was described as still flat, though management said they were hearing that volumes are back for several customers, which could translate into future investments.

Internationally, management said the pharma sector is improving in Europe and the Americas. They also referenced recent large orders in the US and some recovery in China, while noting Europe remains slower structurally. They also discussed a focus on strengthening services and aftermarket in CRT, which has a large installed base.

PPT order intake growth was explained as broad-based across geographies, including traction in mixing. Management also mentioned that cross-selling has improved even after creating distinct verticals, which they said was not an expected primary driver when the new structure was designed.

The margin and earnings-conversion agenda is now explicit

While PAT growth looked strong in Q1 FY27, the bigger question management addressed was the conversion from EBIT to PAT. The company laid out a set of initiatives intended to reduce finance cost, simplify tax and entity structures, and reduce FX and other leakages below EBIT.

The investor presentation listed three specific initiatives with timelines.

First is refinancing and debt reduction, with a stated horizon of 12 to 18 months. Management reiterated that around EUR 7 million of debt is planned to be repaid by the end of Q2 FY27, funded through internal accruals. They also said refinancing opportunities are being evaluated to optimise borrowing costs and maturities.

Second is a group tax strategy and legal entity simplification, with a 18 to 24 month timeline. On the call, the CFO said that the inherited global structure includes multiple legal entities across several countries, which adds complexity. The company expects that simplification should improve financial efficiency and earnings quality over time.

Third is intercompany loan termination, planned over 12 to 18 months, intended to reduce FX and tax exposure sitting below EBIT.

The tone from management was that this is not a one-quarter exercise, but a multi-quarter value creation program.

What management did and did not guide

The company avoided giving a hard timeline to reach a specific EBITDA margin, but reiterated that 15% is a minimum target it aspires to. It also did not provide a quantified debt target for the end of FY27, beyond the near-term EUR 7 million repayment.

However, management did provide a few modelling anchors on the call.

The CFO indicated that interest costs are typically in the 6% to 7% range, with international borrowings linked to SOFR and EURIBOR, and that the debt is hedged. On the effective tax rate, the CFO suggested a long-term steady state of around 30%, possibly slightly lower, but said it could take 18 to 24 months to stabilise depending on debt and organisational restructuring.

Takeaways

Q1 FY27 reinforced two parallel realities for GMM Pfaudler. Operationally, the company is executing well enough to grow revenue at a healthy pace and build a record backlog, with order momentum supported by diversification beyond traditional chemicals and pharmaceuticals. Strategically, the company has begun a reshaping of its operating model, moving from a geography-led structure to a global technology-led structure.

At the same time, the numbers show that profitability remains a work in progress, with EBITDA margin still below the company’s stated aspiration and management acknowledging underperforming units within the group. The next few quarters are likely to be judged less on the existence of a plan and more on measurable progress: stabilising margins, improving cash generation, and translating EBIT into PAT through lower finance, tax, and FX leakage.